Zepbound 2.5 mg/.5mL

Tirzepatide, the active ingredient in Zepbound 2.5 mg/.5mL, is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist presented as a 2.5 mg/.5mL injection, solution for subcutaneous use. It is indicated for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, as an adjunct to diet and physical activity.[2]

GNH USA supplies Zepbound 2.5 mg/.5mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zepbound contains tirzepatide and acts on incretin pathways used in metabolic disease management.[2] - Chronic weight management in adults with obesity: supports treatment alongside reduced-calorie diet and increased physical activity in eligible patients.[2] - Chronic weight management in adults who are overweight and have at least one weight-related comorbidity: helps lower body weight in patients whose excess weight is associated with conditions such as hypertension, dyslipidaemia or type 2 diabetes risk.[2]

Like all prescription injections, Zepbound may cause adverse reactions. Reported effects range from common gastrointestinal symptoms to rarer but more serious safety concerns.[2] Common Side Effects: - Nausea: one of the most frequently reported adverse effects.[2] - Diarrhea: can occur during treatment, especially early in therapy.[2] - Vomiting: may be associated with reduced food intake and dehydration risk.[2] - Constipation: has been reported among common gastrointestinal effects.[2] Serious or Rare Side Effects: - Pancreatitis: severe persistent abdominal pain requires urgent assessment.[2] - Gallbladder problems: including cholelithiasis or cholecystitis.[2] - Hypoglycaemia: risk is higher when used with insulin or insulin secretagogues.[2] - Acute kidney injury: may occur in the setting of severe dehydration from vomiting or diarrhoea.[2]

Zepbound is a prescription injection with important warnings and handling requirements. Clinical monitoring and label-directed use are essential.[2] - Screen for contraindications: do not use in patients with a personal or family history of medullary thyroid carcinoma or in those with MEN 2.[2] - Review pancreatitis history: discontinue and evaluate if symptoms suggest acute pancreatitis.[2] - Assess gallbladder risk: report right upper abdominal pain, fever or jaundice promptly.[2] - Use caution with hypoglycaemia-prone therapy: insulin or sulfonylureas may increase low-blood-sugar risk.[2] - Monitor hydration: persistent vomiting or diarrhoea can worsen renal function.[2] - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.[2]

Tirzepatide can interact clinically with other glucose-lowering medicines and with drugs whose absorption may be affected by delayed gastric emptying.[2] Major Interactions (Avoid): - Hypoglycaemic combination risk: avoid unplanned use with insulin or sulfonylureas without prescriber review because low blood sugar may occur.[2] - Severe intolerance risk: avoid duplicate incretin-based therapy unless specifically directed, as additive GI effects are possible.[2] Moderate Interactions (Monitor Closely): - Oral medicines with narrow timing needs: delayed gastric emptying may affect absorption of some drugs.[2] - Antidiabetic therapy adjustments: blood glucose may change when tirzepatide is added to an existing regimen.[2] - Dehydration-promoting medicines: diuretics or other agents that worsen fluid loss may increase renal risk if vomiting or diarrhoea occur.[2]